Autolus Therapeutics has received FDA approval for its cell therapy to treat aggressive blood cancer. The therapy, known as Aucatzyl, targets B-cell precursor acute lymphoblastic leukemia by engineering T cells to go after CD19, a protein abundant in abnormal cells. Aucatzyl offers better safety and efficacy compared to other treatments, with a faster “off-rate” designed to reduce adverse effects and improve durability. The therapy showed promising results in a clinical trial, with low rates of severe complications. Analysts predict Aucatzyl could become the preferred treatment option for adult ALL patients, with potential expansion into autoimmune disorders.
Source link
‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer
